Progressive Supranuclear Palsy - Pipeline Review, H2 2019

December 2019 | 112 pages | ID: P76BF2F6811EN
Global Markets Direct

Abstracts

Progressive Supranuclear Palsy - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Pipeline Review, H2 2019, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.

Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 3, 8, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Progressive Supranuclear Palsy - Overview
Progressive Supranuclear Palsy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Progressive Supranuclear Palsy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development
AbbVie Inc
Alterity Therapeutics Ltd
AlzProtect SAS
Arvinas Inc
Asceneuron SA
AZTherapies Inc
Biogen Inc
Cerebrum Therapeutics Inc
Cortice Biosciences Inc
Declion Pharmaceuticals Inc
EmeraMed Ltd
K-Stemcell Co Ltd
Merck & Co Inc
New Amsterdam Sciences Inc
Prothena Corp Plc
Retrotope Inc
TauRx Therapeutics Ltd
UCB SA
Voyager Therapeutics Inc
Progressive Supranuclear Palsy - Drug Profiles
ABBV-8E12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASN-120290 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Astrostem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZP-2006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Progressive Supranuclear Palsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPC-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emeramide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy To Inhibit Tau for Dementia and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gosuranemab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydromethylthionine mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8719 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Tau for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit tau Protein for Alzhiemer's Disease and Progressive Supranuclear Palsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAS-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAS-150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBT-434 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Progressive Supranuclear Palsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Microtubule Associated Protein Tau for Alzheimer's Disease and Progressive Supranuclear Palsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBL-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tolfenamic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPI-287 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UCB-0107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Progressive Supranuclear Palsy - Dormant Projects
Progressive Supranuclear Palsy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Progressive Supranuclear Palsy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Progressive Supranuclear Palsy - Pipeline by AbbVie Inc, H2 2019
Progressive Supranuclear Palsy - Pipeline by Alterity Therapeutics Ltd, H2 2019
Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, H2 2019
Progressive Supranuclear Palsy - Pipeline by Arvinas Inc, H2 2019
Progressive Supranuclear Palsy - Pipeline by Asceneuron SA, H2 2019
Progressive Supranuclear Palsy - Pipeline by AZTherapies Inc, H2 2019
Progressive Supranuclear Palsy - Pipeline by Biogen Inc, H2 2019
Progressive Supranuclear Palsy - Pipeline by Cerebrum Therapeutics Inc, H2 2019
Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences Inc, H2 2019
Progressive Supranuclear Palsy - Pipeline by Declion Pharmaceuticals Inc, H2 2019
Progressive Supranuclear Palsy - Pipeline by EmeraMed Ltd, H2 2019
Progressive Supranuclear Palsy - Pipeline by K-Stemcell Co Ltd, H2 2019
Progressive Supranuclear Palsy - Pipeline by Merck & Co Inc, H2 2019
Progressive Supranuclear Palsy - Pipeline by New Amsterdam Sciences Inc, H2 2019
Progressive Supranuclear Palsy - Pipeline by Prothena Corp Plc, H2 2019
Progressive Supranuclear Palsy - Pipeline by Retrotope Inc, H2 2019
Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd, H2 2019
Progressive Supranuclear Palsy - Pipeline by UCB SA, H2 2019
Progressive Supranuclear Palsy - Pipeline by Voyager Therapeutics Inc, H2 2019
Progressive Supranuclear Palsy - Dormant Projects, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Progressive Supranuclear Palsy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

AbbVie Inc
Alterity Therapeutics Ltd
AlzProtect SAS
Arvinas Inc
Asceneuron SA
AZTherapies Inc
Biogen Inc
Cerebrum Therapeutics Inc
Cortice Biosciences Inc
Declion Pharmaceuticals Inc
EmeraMed Ltd
K-Stemcell Co Ltd
Merck & Co Inc
New Amsterdam Sciences Inc
Prothena Corp Plc
Retrotope Inc
TauRx Therapeutics Ltd
UCB SA
Voyager Therapeutics Inc